Duration of fever in children infected with influenza A(H1N1)pdm09, A(H3N2) or B virus and treated with baloxavir marboxil, oseltamivir, laninamivir, or zanamivir in Japan during the 2012-2013 and 2019-2020 influenza seasons.

Autor: Sun Y; Division of International Health (Public Health), Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan. Electronic address: sunyuyang@med.niigata-u.ac.jp., Wagatsuma K; Division of International Health (Public Health), Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan., Saito R; Division of International Health (Public Health), Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan., Sato I; Yoiko Pediatric Clinic, Niigata, Japan., Kawashima T; Kawashima Internal Medicine Clinic, Gunma, Japan., Saito T; Tako Central Hospital, Chiba, Japan., Shimada Y; Shimada Children's Clinic, Kumamoto, Japan., Ono Y; Ono Pediatric Clinic, Nagasaki, Japan., Kakuya F; Furano Kyokai Hospital, Hokkaido, Japan., Minato M; Minato Pediatric Clinic, Tokyo, Japan., Kodo N; Kodo Pediatric Clinic, Kyoto, Japan., Suzuki E; Suzuki Pediatric Clinic, Yamaguchi, Japan., Kitano A; Kitano Pediatric Clinic, Kumamoto, Japan., Chon I; Division of International Health (Public Health), Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan., Phyu WW; Division of International Health (Public Health), Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan., Li J; Division of International Health (Public Health), Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan., Watanabe H; Infectious Diseases Research Center of Niigata University in Myanmar (IDRC), Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan.
Jazyk: angličtina
Zdroj: Antiviral research [Antiviral Res] 2024 Aug; Vol. 228, pp. 105938. Date of Electronic Publication: 2024 Jun 17.
DOI: 10.1016/j.antiviral.2024.105938
Abstrakt: We compared the duration of fever in children infected with A(H1N1)pdm09, A(H3N2), or influenza B viruses following treatment with baloxavir marboxil (baloxavir) or neuraminidase inhibitors (NAIs) (oseltamivir, zanamivir, or laninamivir). This observational study was conducted at 10 outpatient clinics across 9 prefectures in Japan during the 2012-2013 and 2019-2020 influenza seasons. Patients with influenza rapid antigen test positive were treated with one of four anti-influenza drugs. The type/subtype of influenza viruses were identified from MDCK or MDCK SIAT1 cell-grown samples using two-step real-time PCR. Daily self-reported body temperature after treatment were used to evaluate the duration of fever by treatment group and various underlying factors. Among 1742 patients <19 years old analyzed, 452 (26.0%) were A(H1N1)pdm09, 827 (48.0%) A(H3N2), and 463 (26.0%) influenza B virus infections. Among fours treatment groups, baloxavir showed a shorter median duration of fever compared to oseltamivir in univariate analysis for A(H1N1)pdm09 virus infections (baloxavir, 22.0 h versus oseltamivir, 26.7 h, P < 0.05; laninamivir, 25.5 h, and zanamivir, 25.0 h). However, this difference was not significant in multivariable analyses. For A(H3N2) virus infections, there were no statistically significant differences observed (20.3, 21.0, 22.0, and 19.0 h) uni- and multivariable analyses. For influenza B, baloxavir shortened the fever duration by approximately 15 h than NAIs (20.3, 35.0, 34.3, and 34.1 h), as supported by uni- and multivariable analyses. Baloxavir seems to have comparable clinical effectiveness with NAIs on influenza A but can be more effective for treating pediatric influenza B virus infections than NAIs.
Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.)
Databáze: MEDLINE